Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidoses (MPS) and Gene Therapy
source: American Society of Gene & Cell Therapy
year: 2020
summary/abstract:Mucopolysaccharidoses (MPS) are a group of genetic disorders that affect our body’s ability to break down and recycle sugar molecules called glycosaminoglycans, or GAGs, leading to buildup and causing severe symptoms. Gene therapy targets the root cause of disease and therefore may offer hope for slowing or halting the progression of some MPS disorders.
MPS and Gene Therapy
There are seven different types of MPS, each caused by a different faulty gene. Gene therapy may be able to slow the progression of the MPS disorders I, II, III and VI, although it cannot reverse damage the disease has already caused. You may have heard that MPS I is also known as Hurler syndrome, while MPS II is referred to as Hunter syndrome and MPS III is called Sanfilippo syndrome.
Gene therapy introduces a working version of a gene into the cells in charge of creating key proteins or enzymes. These genetic instructions are delivered to the cells using a vector, or vehicle, which are often derived from viruses. Typically, viruses are used as vectors because they are capable of entering cells to deliver genetic material. Don’t worry. All viral genes are removed and the vector is modified to only deliver therapeutic genes to cells. With the right genetic instructions, cells can then produce functional enzymes that help break down further buildup of GAGs.
read more
Related Content
-
Elosulfase Alfa in the Treatment of Mucopolysaccharidosis Type IVA: Insights From the First Managed Access AgreementManaged access agreements provide a cruc...
-
Mucopolysaccharidoses Fact SheetThe mucopolysaccharidoses are a group of...
-
Mucopolysaccharidosis Market: Global Industry Analysis and Opportunity Assessment 2022-2029The wide ranging Mucopolysaccharidosis M...
-
University of Minnesota – Mucopolysaccharidosis (MPS) CenterOur MPS Center is internationally recogn...
-
iPS-Derived Neural Stem Cells for Disease Modeling and Evaluation of Therapeutics for Mucopolysaccharidosis Type IIMucopolysaccharidosis type II (MPS II), ...
-
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR PharmaceuticalsTakeda Pharmaceutical Company Limited an...
-
Raymond Y. Wang, MDRaymond Wang, M.D. is the Director of th...